From 8557cb9cb8e6edbb742cdb01e596fcc33614ab6f Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Sat, 11 Apr 2026 04:24:22 +0000 Subject: [PATCH] vida: extract claims from 2025-12-xx-lancet-psychiatry-antidepressant-deprescribing-nma-slow-taper-therapy - Source: inbox/queue/2025-12-xx-lancet-psychiatry-antidepressant-deprescribing-nma-slow-taper-therapy.md - Domain: health - Claims: 1, Entities: 0 - Enrichments: 0 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida --- ...t-psychological-support-mitigates-relapse.md | 17 +++++++++++++++++ 1 file changed, 17 insertions(+) create mode 100644 domains/health/antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse.md diff --git a/domains/health/antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse.md b/domains/health/antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse.md new file mode 100644 index 000000000..0d933df1e --- /dev/null +++ b/domains/health/antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse.md @@ -0,0 +1,17 @@ +--- +type: claim +domain: health +description: Psychiatric pharmacotherapy shows the same benefit-reversion pattern as metabolic drugs but has a mitigation pathway through behavioral intervention that metabolic treatments lack +confidence: likely +source: The Lancet Psychiatry, network meta-analysis of 76 RCTs with 17,000+ adults +created: 2026-04-11 +title: "Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication" +agent: vida +scope: causal +sourcer: The Lancet Psychiatry +related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"] +--- + +# Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication + +Network meta-analysis of 76 randomized controlled trials with over 17,000 adults in clinically remitted depression shows that antidepressant discontinuation follows a continuous-treatment pattern: relapse rates reach 34.81% at 6 months and 45.12% at 12 months after discontinuation. However, slow tapering (>4 weeks) combined with psychological support achieves equivalent relapse prevention to remaining on antidepressants (relative risk 0.52; NNT 5.4). This reveals a critical structural difference from metabolic interventions like GLP-1 agonists: psychiatric pharmacotherapy can be partially substituted by behavioral/cognitive interventions during discontinuation, while metabolic treatments show no such mitigation pathway. Abrupt discontinuation shows clearly higher relapse risk, confirming the continuous-treatment pattern, but the effectiveness of gradual tapering plus therapy demonstrates that the durability profile of interventions differs by mechanism—behavioral interventions can create lasting cognitive/emotional skills that reduce relapse risk, while metabolic interventions address physiological states that fully revert without ongoing treatment. The finding that continuation plus psychological support outperformed abrupt discontinuation (RR 0.40; NNT 4.3) while slow taper plus support matched continuation suggests psychological support is the active ingredient enabling safe discontinuation, not merely time-based tapering.